prikaz prve stranice dokumenta Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
  Preuzmi
PDF 808.64 KB
Znanstveni rad - Izvorni znanstveni rad
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
Cancers, 14 (2022), 22; 5530. https://doi.org/10.3390/cancers14225530
Cattaneo, Chiara; Salmanton-García, Jon; Marchesi, Francesco; El-Ashwah, Shaimaa; Itri, Federico; Weinbergerová, Barbora; Gomes Da Silva, Maria; Dargenio, Michelina; Dávila-Valls, Julio; Martín-Pérez, Sonia; Farina, Francesca; Van Doesum, Jaap; Valković, Toni; Besson, Caroline; Poulsen, Christian Bjørn; López-García, Alberto; Žák, Pavel; Schönlein, Martin; Piukovics, Klára; Jakšić, Ozren; Cabirta, Alba; Ali, Natasha; Sili, Uluhan; Fracchiolla, Nicola; Dragonetti, Giulia; Adžić-Vukičević, Tatjana; Marchetti, Monia; Machado, Marina; Glenthøj, Andreas; Finizio, Olimpia; Demirkan, Fatih; Blennow, Ola; Tisi, Maria Chiara; Omrani, Ali S.; Navrátil, Milan; Ráčil, Zdeněk; Novák, Jan; Magliano, Gabriele; Jiménez, Moraima; Garcia-Vidal, Carolina; Erben, Nurettin; Del Principe, Maria Ilaria; Buquicchio, Caterina; Bergantim, Rui; Batinić, Josip; Al-Khabori, Murtadha; Verga, Luisa; Szotkowski, Tomáš; Samarkos, Michail; Ormazabal-Vélez, Irati; Meers, Stef; Maertens, Johan; Pinczés, László Imre; Hoenigl, Martin; Drgoňa, Ľuboš; Cuccaro, Annarosa; Bilgin, Yavuz M.; Aujayeb, Avinash; Rahimli, Laman; Gräfe, Stefanie; Sciumè, Mariarita; Mladenović, Miloš; Çolak, Gökçe Melis; Sacchi, Maria Vittoria; Nordlander, Anna; Berg Venemyr, Caroline; Hanáková, Michaela; García-Poutón, Nicole; Emarah, Ziad; Zambrotta, Giovanni Paolo Maria; Nunes Rodrigues, Raquel; Cordoba, Raul; Méndez, Gustavo-Adolfo; Biernat, Monika M.; Cornely, Oliver A.; Pagano, Livio Više autora...

Citirajte ovaj rad

Cattaneo, C., Salmanton García, J., Marchesi, F., El Ashwah, S., Itri, F., Weinbergerová, B. ... Pagano, L. (2022). Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. Cancers, 14. (22). doi: 10.3390/cancers14225530

Cattaneo, Chiara, et al. "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey." Cancers, vol. 14, br. 22, 2022. https://doi.org/10.3390/cancers14225530

Cattaneo, Chiara, Jon Salmanton García, Francesco Marchesi, Shaimaa El Ashwah, Federico Itri, Barbora Weinbergerová, Maria Gomes Da Silva, et al. "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey." Cancers 14, br. 22 (2022). https://doi.org/10.3390/cancers14225530

Cattaneo, C., et al. (2022) 'Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey', Cancers, 14(22). doi: 10.3390/cancers14225530

Cattaneo C, Salmanton García J, Marchesi F, El Ashwah S, Itri F, Weinbergerová B, i sur.. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. Cancers [Internet]. 10.11.2022. [pristupljeno 10.11.2024.];14(22). doi: 10.3390/cancers14225530

C. Cattaneo, et al., "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey", Cancers, vol. 14, br. 22, Studeni 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:096700. [Citirano: 10.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:096700
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
AutorChiara Cattaneo
AutorJon Salmanton-García
AutorFrancesco Marchesi
AutorShaimaa El-Ashwah
AutorFederico Itri
AutorBarbora Weinbergerová
AutorMaria Gomes Da Silva
AutorMichelina Dargenio
AutorJulio Dávila-Valls
AutorSonia Martín-Pérez
AutorFrancesca Farina
AutorJaap Van Doesum
AutorToni Valković
AutorCaroline Besson
AutorChristian Bjørn Poulsen
AutorAlberto López-García
AutorPavel Žák
AutorMartin Schönlein
AutorKlára Piukovics
AutorOzren Jakšić
AutorAlba Cabirta
AutorNatasha Ali
AutorUluhan Sili
AutorNicola Fracchiolla
AutorGiulia Dragonetti
AutorTatjana Adžić-Vukičević
AutorMonia Marchetti
AutorMarina Machado
AutorAndreas Glenthøj
AutorOlimpia Finizio
AutorFatih Demirkan
AutorOla Blennow
AutorMaria Chiara Tisi
AutorAli S. Omrani
AutorMilan Navrátil
AutorZdeněk Ráčil
AutorJan Novák
AutorGabriele Magliano
AutorMoraima Jiménez
AutorCarolina Garcia-Vidal
AutorNurettin Erben
AutorMaria Ilaria Del Principe
AutorCaterina Buquicchio
AutorRui Bergantim
AutorJosip Batinić
AutorMurtadha Al-Khabori
AutorLuisa Verga
AutorTomáš Szotkowski
AutorMichail Samarkos
AutorIrati Ormazabal-Vélez
AutorStef Meers
AutorJohan Maertens
AutorLászló Imre Pinczés
AutorMartin Hoenigl
AutorĽuboš Drgoňa
AutorAnnarosa Cuccaro
AutorYavuz M. Bilgin
AutorAvinash Aujayeb
AutorLaman Rahimli
AutorStefanie Gräfe
AutorMariarita Sciumè
AutorMiloš Mladenović
AutorGökçe Melis Çolak
AutorMaria Vittoria Sacchi
AutorAnna Nordlander
AutorCaroline Berg Venemyr
AutorMichaela Hanáková
AutorNicole García-Poutón
AutorZiad Emarah
AutorGiovanni Paolo Maria Zambrotta
AutorRaquel Nunes Rodrigues
AutorRaul Cordoba
AutorGustavo-Adolfo Méndez
AutorMonika M. Biernat
AutorOliver A. Cornely
AutorLivio Pagano
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCancers
Brojčani podacivol. 14, br. 22, 5530
e-ISSN2072-6694
DOIhttps://doi.org/10.3390/cancers14225530
URN:NBNurn:nbn:hr:105:096700
Datum objave publikacije2022-11-10
URL dokumentahttps://www.mdpi.com/2072-6694/14/22/5530
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-06-13 11:27:12